The European Society for Medical Oncology (ESMO) has issued its inaugural guidance on using large language models (LLMs) in cancer care, emphasizing the potential benefits of AI for patients while recognizing the lack of comprehensive evaluations regarding associated risks. Published in the Annals of Oncology during the annual ESMO meeting in Berlin, these guidelines highlight the urgency for oncologists to understand and harness AI technology responsibly. While the American Society of Clinical Oncology has shared principles for AI use in cancer treatment, it has not provided specific recommendations for LLMs. The integration of AI in oncology aims to enhance patient outcomes, yet requires careful consideration to mitigate risks. As the field evolves, continuous evaluation of generative AI tools is crucial for ensuring safety and efficacy in cancer medicine. For further insights and detailed analysis of healthcare technologies, consider subscribing to STAT+.
